Key Points
The AP-1/TNF-α transcriptional program is upregulated in MLL-AF9–driven leukemic cells originating from JAM-C deleted mouse.
Stratification of patients with AML using LSC score (LSC-17) is improved by the score associated with AP-1/TNF-α gene signature.
Visual Abstract
The leukemic stem cell (LSC) score LSC-17 based on a stemness–related gene expression signature is an indicator of poor disease outcome in acute myeloid leukemia (AML). However, it is not known whether “niche anchoring” of LSC affects disease evolution. To address this issue, we conditionally inactivated the adhesion molecule JAM-C (Junctional Adhesion Molecule-C) expressed by hematopoietic stem cells (HSCs) and LSCs in an inducible mixed-lineage leukemia (iMLL)-AF9–driven AML mouse model. Deletion of Jam3 (encoding JAM-C) before induction of the leukemia–initiating iMLL-AF9 fusion resulted in a shift from long-term to short-term HSC expansion, without affecting disease initiation and progression. In vitro experiments showed that JAM-C controlled leukemic cell nesting irrespective of the bone marrow stromal cells used. RNA sequencing performed on leukemic HSCs isolated from diseased mice revealed that genes upregulated in Jam3-deficient animals belonged to activation protein-1 (AP-1) and tumor necrosis factor α (TNF-α)/NF-κB pathways. Human orthologs of dysregulated genes allowed to identify a score that was distinct from, and complementary to, the LSC-17 score. Substratification of patients with AML using LSC-17 and AP-1/TNF-α genes signature defined 4 groups with median survival ranging from <1 year to a median of “not reached” after 8 years. Finally, coculture experiments showed that AP-1 activation in leukemic cells was dependent on the nature of stromal cells. Altogether, our results identify the AP-1/TNF-α gene signature as a proxy of LSC anchoring in bone marrow niches, which improves the prognostic value of the LSC-17 score. This trial was registered at www.ClinicalTrials.gov as #NCT02320656.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous disease that originates from genetic alterations and clonal expansion of hematopoietic stem and progenitor cells (HSPCs). The organization of leukemic cells in AML is similar to normal hematopoiesis with leukemic stem cells (LSCs) at the apex that can reconstitute the clonal heterogeneity of AML disease in xenograft experiments.1 LSCs are thought to be involved in AML relapse and enriched within, but not restricted to the CD34+/CD38− phenotypic compartment.2,3 Additional LSCs markers have thus been described including CD123, CD44, CLL1, CD96, CD47, TIM-3, CD32, CD25, IL1RAP, CD33, CD93, CD98, CD99, CD117, GPR56/ADGRG1, and JAM-C.3-18 However, none of them, used alone or in combination, is necessary or sufficient to identify pure population of cells with leukemic initiating activity within or across patient samples, merely reflecting the heterogeneity of LSC in AML.19,20 This prompted several teams to search for proxies reflecting the abundance of cells with leukemia-initiating activity that may predict disease outcome. Several gene expression signatures have been associated with poor prognosis21-23 and some of them relied on increased frequencies of primitive quiescent LSCs in AML.12,24-26 Among them, the leukemic stemness LSC-17 score represents 1 of the most robust LSC gene expression signatures, showing that the cellular hierarchy influences the overall characteristics of AML.27 Other experimental approaches to identify hallmarks of LSCs comprised deciphering cellular heterogeneity of AML disease using single-cell RNA sequencing.28-30 This allowed for the identification of differentially expressed genes (DEGs) in hematopoietic stem cell (HSC)–like cells as compared with more mature leukemic cells, some of which (MMRN1, CD34, SOCS2, SMIM24, FAM30A, and CDK6) are also included in the leukemic stemness LSC-17 score. Finally, modeling AML disease in mice identified features of leukemia-initiating cells.31 Expression of the mixed-lineage leukemia (MLL)-AF9 gene fusion induced transformation of HSPCs, which were able to reconstitute the disease.32 Further studies using Mll-AF9 heterozygous knockin mice33 demonstrated that the most aggressive leukemia originated in HSCs rather than in more mature granulocyte/monocyte progenitors (GMPs).34-36 More recently, study of the inducible MLL-AF9 (iMLL-AF9) model revealed that aggressiveness was correlated with high HSC expression of genes related to epithelial mesenchymal transition or cell adhesion.37 This was consistent with our finding showing that human LSC (CD45dimCD34+CD38lowCD123+) expressing the adhesion molecule JAM-C (Junctional Adhesion Molecule-C, encoded by JAM3) also expressed high levels of ALCAM or ITGA6, and that high frequency of JAM-C–expressing cells at diagnosis was associated with poor disease outcome.4 These results suggest, but do not prove, that LSC adhesion to the surrounding bone marrow stromal cells (BMSCs) plays a role in AML disease initiation and outcome.
To model loss of LSC adhesion anchoring to BMSCs, we crossed conditional Jam3-deficient mice with the iMLL-AF9 leukemia model. Although Jam3 deficiency did not delay disease evolution, we found upregulation of genes belonging to activation protein-1 (AP-1) and tumor necrosis factor α (TNF-α) pathways in Jam3-deleted LSCs as compared with control leukemic animals. Transposition of the results to the human disease allowed to define a new prognosis score called ATIC (AP-1/TNF-α initiating cells) that is complementary and distinct from the LSC-17 score.
Methods
Human samples
Human peripheral blood samples were collected with informed consent in the frame of NCT02320656 clinical trial according to the procedure approved by the institutional review board of Institut Paoli-Calmettes as sponsor of the study. Vials were thawed in, and thereafter washed in, RPMI 1640 containing 30% fetal calf serum (FCS), 1% penicillin/streptomycin, 100 U/mL DNase, and 10 U/mL of heparin. Dead cells were removed by layering 1 mL of cell suspension onto 2 mL of Ficoll followed by centrifugation for 20 minutes at 2000 RPM, after which cells were washed and maintained in RPMI 1640 containing 10% FCS and 1% penicillin/streptomycin until further use.
Mice experiments
iMLL-AF9 mice were crossed with Mx1-Cre Jam3fl/fl mice. Jam3fl/fl mice have been described previously.38 All experiments were performed in compliance with the laws and protocols approved by animal ethics committees. Baseline white blood cell count (WBC) was assessed on day 0 in iMLL Jam3fl/fl mice, and Jam3 gene deletion was induced by 3 intraperitoneal injections of 200 μg poly (I:C) (polyinosinic-polycytidylic acid; InvivoGen) on day 1, 3, and 5. Doxycycline (DOX; 400 μg/mL; Sigma) was provided in drinking water supplemented with 5% sucrose, 9 days after the last poly (I:C) injection. Leukemic burden was monitored weekly after WBC (ProCyte Dx Hematology Analyzer, IDEXX Laboratories).
Flow cytometry and cell sorting
Human samples were stained with antibodies described in supplemental Table 1 in phosphate-buffered saline containing 0.5 mM EDTA and 2% FCS (30 minutes at 4°C), washed, and processed for analysis. Mouse samples recovered from the femur and tibia were treated with 1× red blood cell lysing buffer (eBioscience) and stained with antibodies described in supplemental Table 1. Fluorescence-activated cell sorting analysis was performed on LSRII (BD Biosciences) or Aurora (Cytek). Cell sorting was performed using FACSAria III (BD Biosciences). Data were analyzed using DIVA version 8.01 (BD Biosciences) or OMIQ (OMIQ Inc).
RNA sequencing
HSCs and GMPs were directly sorted in RLT buffer from a messenger RNA (mRNA) purification kit using the RNeasy micro kit (QIAGEN). Samples were sent to the GenomEast platform (Illkirch, France). Libraries were paired-end sequenced (2 × 100 base pairs) on a Hiseq4000 system (Illumina).
Nanostring assay
Total mRNA from patient samples extracted using the RNeasy mini kit (QIAGEN) were hybridized with our custom nCounter Nanostring Code Set (supplemental Table 2) according to manufacturer instructions. Results were normalized using nSolver software (version 4.0), and log2 transformed values were used for LSC-17 score calculation.
Statistical analysis
Statistical analysis was performed using GraphPad 6 software and error bars represent the mean ± standard error of the mean. Normality was assayed using D’Agostino and Pearson omnibus normality test and samples were compared with a Mann-Whitney U test when normality was not reached. ∗P < .05; ∗∗P < .01; and ∗∗∗P < .001.
Publicly available data sets used for model training and validation
Publicly available mRNA sequencing data sets from the TCGA and OHSU cohort (also known as BEAT AML cohort39) were retrieved from cBioPortal using the CGDS-R package. The Leucegene data set was retrieved from Gene Expression Omnibus data repository (accession number GSE67040) and merged with clinical annotations. The 3 cohorts were assembled in a single matrix of gene expression, scaled, centered and half-split in training and validation cohorts. The ATIC score was established as the weighted sum of 14 gene expression as follow: ATIC score = (−0.02537109 × JAM3) + (−0.03654864 × DUSP1) + (−0.007206288 × RGS1) + (0.008025696 × H2BC8) + (−0.01143364 × NFKBID) + (−0.00423489 × ZFP36) + (−0.05511406 × SLFN12) + (−0.3608987 × GAS5) + (0.1012163 × RPP25L) + (0.05303331 × HEY1) + (−0.01449147 × GIMAP4) + (0.09348158 × EFCAB11) + (−0.03832157 × CCL4) + (−0.01028905 × MYCN). The gene expression data set from the HOVON/SAKK cohort (662 adult AML cases) was retrieved from the ArrayExpress database (accession number E-MTAB-3444) and gcrma maxVar expression values were used to calculate LSC-17 and ATIC scores.
Coculture experiments
For coculture experiments, 1 × 106 HS-5 or 8 × 105 HS-27 stromal cells were plated in 6-wells plates. Two days later, SKM1JAM-C+ or SKM1JAM-C− cells were respectively labeled with calcein AM (C3100MP, ThermoFisher) and calcein red orange AM (C34851, ThermoFisher) for 30 minutes in phosphate-buffered saline, washed, mixed 1:1, and overlayed (2 × 106 cells) onto the stromal monolayers. After 7 hours of coculture, nonadherent, adherent, and nested cells were respectively collected by gentle aspiration, flushing, and trypsin digestion before analysis by flow cytometry. Leukemic cells were gated using CD45 staining (catalog no. 564357, BD) and results were expressed as ratios of calcein AM (SKM1JAM-C+) and calcein red orange (SKM1JAM-C−) cells.
Cell transduction
Lentiviral particles containing mock or AP-1–green fluorescent protein (GFP) reporter (TR411VA-P and TR452VA-P, respectively; System Biosciences) were transduced in SKM1JAM-C+ or SKM1JAM-C−. Cells were mixed with viral vectors at the multiplicity of infection of 10 (MOI 10) and 8 μg/mL of Polybrene before spinoculation at 1500g over 45 minutes. After 48 hours, transduced cells were selected with 0.6 μg/mL of puromycin for 7 days. AP-1 reporter expression was confirmed by stimulation with 20 ng/mL phorbol myristate acetate (PMA) for 24 hours, and analyzed by flow cytometry.
Results
JAM-C identifies a subset of LSCs
To address the phenotypic heterogeneity of LSCs, we conducted a correlation study of “LSC marker” gene expression across 3 cohorts of patients with AML (OHSU, TCGA, Leucegene).39-41 Correlated expression between GPR56 and JAM-C or CD93 and CD32 were systematically found, whereas correlation between other “LSC markers” varied from cohort to cohort (Figure 1A). We thus focused on GPR56 and JAM-C markers, which were highly significantly correlated (Figure 1B). Both markers were tested by flow cytometry in combination with live-dead, CD34, CD38, CD41, CD123, CD33, and CD45 in 62 blood samples from patients with AML (Table 1). Uniform manifold approximation and projection42 analysis of JAM-C–expressing cells showed that most of the cells belonged to the CD34+/GPR56+/CD38−/low compartment (Figure 1C). Conversely, GPR56+ cells expressed various levels of CD34, CD38, and JAM-C (supplemental Figure 1A), and higher frequencies of JAM-C+/GPR56+ cells were found in the CD34+CD38−/low most-immature compartment (Figure 1D). JAM-C–expressing cells represented <1% of GPR56+ cells and were almost absent from the most-mature CD34−GPR56− compartment (Figure 1E). Because GPR56 gene expression is contributing to the LSC-17 score, we tested whether JAM3 expression was associated with the LSC-17 score. Results showed that JAM3 (encoding JAM-C) and GPR56 expression were significantly higher in samples belonging to the LSC-17High group (supplemental Figure 1B).
ID . | Diagnosis . | FAB . | Karyotype . | WBC (x109/L) . |
---|---|---|---|---|
Patient no. 1 | De novo | M4 | 47,XX,+8[20] | 9.6 |
Patient no. 2 | De novo | M2 | 46,XX,T(8;21)(Q22;Q22)[6]/46,IDEM,DEL(7)(Q21Q36)[13]/46,XX[1] | 1.9 |
Patient no. 3 | sAML (after MDS) | M1 | Complex monosomal | 15.1 |
Patient no. 4 | De novo Relapse | M1 | 46,XX[20] | 176.5 |
Patient no. 5 | De novo | M2 | 47,XX,+11[4]/46,XX[16] | 2.3 |
Patient no. 6 | De novo | M1 | 46,XX[20] | 86.3 |
Patient no. 7 | De novo | M4 | 45,X,-Y,T(8;21)(Q22;Q22)[20] | 44.9 |
Patient no. 8 | De novo | M0 | 47,XY,+13[32]/46,XY[4] | 1.4 |
Patient no. 9 | sAML (after MDS) | M2 | 46,XY,DEL(5)(31Q35)[15]/47,IDEM,+14[3]/46,XY[7] | ND |
Patient no. 10 | De novo | M1 | 46,XX[20] | 8.7 |
Patient no. 11 | De novo | M2 | 46,XY[20] | 1.5 |
Patient no. 12 | De novo | M2 | Complex monosomal | 17.4 |
Patient no. 13 | De novo | M4 | 46,XY[20] | 7.3 |
Patient no. 14 | De novo | M4 | Complex monosomal | 11.2 |
Patient no. 15 | De novo | M2 | 46,XX,T(8;21)(Q22;Q22),T(11;17)(Q14;Q11-12)[20] | 4.4 |
Patient no. 16 | De novo | M2 | 47,XX,+8[4]/46,XX[20] | 2.9 |
Patient no. 17 | sAML (after MPN) | M0 | 46,XX,DEL(20)(Q11Q13)[2]/46,IDEM,DEL(7)(Q22Q32)[15]/46,XX[3] | 23.8 |
Patient no. 18 | De novo | NK | Complex monosomal | 11.4 |
Patient no. 19 | sAML (after MDS) | M1 | 46,XY[20] | 59 |
Patient no. 20 | De novo | NK | 47,XY,+8[21]/46,XY[1] | 1.3 |
Patient no. 21 | De novo | M1 | 46,XY[20] | 8.1 |
Patient no. 22 | De novo | M0 | NK | 1 |
Patient no. 23 | De novo | CMML | 46,XY[20] | 47.1 |
Patient no. 24 | De novo | M1 | 46,XX,DEL(7)(Q22Q36)[20] | 8.6 |
Patient no. 25 | De novo | M4 | Complex monosomal | 10 |
Patient no. 26 | De novo | M5 | 46,XY,ADD(17)(P1?3)[14]/46,XY[8] | 35 |
Patient no. 27 | De novo | NK | 46,XY[20] | 5.5 |
Patient no. 28 | De novo | NK | 46,XX[20] | 0.5 |
Patient no. 29 | De novo | M1 | Complex | 2.4 |
Patient no. 30 | De novo | M1 | 47,XX,+10[37]/46,IDEM,DEL(9)(Q12Q32)[3] | 136.9 |
Patient no. 31 | De novo | M4 | 46,XY[20] | 18.8 |
Patient no. 32 | De novo | M0 | 46,XY[40] | 185 |
Patient no. 33 | De novo | M6 | 46,XY,INV(3)(Q21Q26)[20] | 17.6 |
Patient no. 34 | De novo | M5 | Complex | 80.2 |
Patient no. 35 | De novo | M1 | 47,XX,+21[10]/46,XX[11] | 6.7 |
Patient no. 36 | De novo | M0 | 46,XY,?T(3;7;5)(P24;Q36;Q14)[20] | 66 |
Patient no. 37 | De novo | M0 | 46,XX[30] | 2 |
Patient no. 38 | De novo | M4 | 46,XY,INV(16)(P13Q22)[20] | 29.7 |
Patient no. 39 | sAML (after MDS) | M2 | 46,XY[20] | 5.6 |
Patient no. 40 | De novo | M2 | 46,XX[20] | 3.2 |
Patient no. 41 | De novo | M1 | Complex monosomal | 1 |
Patient no. 42 | De novo | M0 | 45,XX,-7,DER(21)T(7;21)(P11;P11)[20] | 2.8 |
Patient no. 43 | De novo | M1 | 46,XX[20] | 51.6 |
Patient no. 44 | De novo | M4 | Complex monosomal | 23.4 |
Patient no. 45 | De novo | M0 | Complex monosomal | 2.5 |
Patient no. 46 | De novo | M5 | 46,XY,T(9;11)(P21-22;Q23)[20] | 169.9 |
Patient no. 47 | sAML (after MPN) | M0 | 46,XY,DEL(7)(Q22Q36)[21]/46,IDEM,I(21)(Q10)[2] | 5.2 |
Patient no. 48 | De novo | M5 | 46,XY,T(6;9)(P22;Q34)[20] | 41.8 |
Patient no. 49 | De novo | M1 | 46,XX[20] | 21.8 |
Patient no. 50 | De novo | M5 | 46,XX,T(11;17)(Q23;Q12-21)[2]/47,IDEM,?DEL(11)(Q23 OR Q22Q24-)+21[20] | 54.1 |
Patient no. 51 | De novo | M2 | 46,XY[20] | 3.32 |
Patient no. 52 | De novo | M4 | 46,XX[20] | 19.1 |
Patient no. 53 | De novo | M2 | 46,XX[20] | 3.9 |
Patient no. 54 | De novo | M2 | 46,XY[20] | 48.9 |
Patient no. 55 | De novo | M2 | 46,XX[20] | 6.9 |
Patient no. 56 | De novo | NK | Complex monosomal | 17.5 |
Patient no. 57 | De novo | M5 | 47,XY,+21[21]/46,XY[1] | 29 |
Patient no. 58 | De novo | M2 | 45,XY,-7[3]/46,XY[17] | 146 |
Patient no. 59 | De novo | M4 | Complex monosomal | 2.5 |
Patient no. 60 | Patient no. 14 relapse | |||
Patient no. 61 | Patient no. 31 relapse | |||
Patient no. 62 | Patient no. 40 relapse |
ID . | Diagnosis . | FAB . | Karyotype . | WBC (x109/L) . |
---|---|---|---|---|
Patient no. 1 | De novo | M4 | 47,XX,+8[20] | 9.6 |
Patient no. 2 | De novo | M2 | 46,XX,T(8;21)(Q22;Q22)[6]/46,IDEM,DEL(7)(Q21Q36)[13]/46,XX[1] | 1.9 |
Patient no. 3 | sAML (after MDS) | M1 | Complex monosomal | 15.1 |
Patient no. 4 | De novo Relapse | M1 | 46,XX[20] | 176.5 |
Patient no. 5 | De novo | M2 | 47,XX,+11[4]/46,XX[16] | 2.3 |
Patient no. 6 | De novo | M1 | 46,XX[20] | 86.3 |
Patient no. 7 | De novo | M4 | 45,X,-Y,T(8;21)(Q22;Q22)[20] | 44.9 |
Patient no. 8 | De novo | M0 | 47,XY,+13[32]/46,XY[4] | 1.4 |
Patient no. 9 | sAML (after MDS) | M2 | 46,XY,DEL(5)(31Q35)[15]/47,IDEM,+14[3]/46,XY[7] | ND |
Patient no. 10 | De novo | M1 | 46,XX[20] | 8.7 |
Patient no. 11 | De novo | M2 | 46,XY[20] | 1.5 |
Patient no. 12 | De novo | M2 | Complex monosomal | 17.4 |
Patient no. 13 | De novo | M4 | 46,XY[20] | 7.3 |
Patient no. 14 | De novo | M4 | Complex monosomal | 11.2 |
Patient no. 15 | De novo | M2 | 46,XX,T(8;21)(Q22;Q22),T(11;17)(Q14;Q11-12)[20] | 4.4 |
Patient no. 16 | De novo | M2 | 47,XX,+8[4]/46,XX[20] | 2.9 |
Patient no. 17 | sAML (after MPN) | M0 | 46,XX,DEL(20)(Q11Q13)[2]/46,IDEM,DEL(7)(Q22Q32)[15]/46,XX[3] | 23.8 |
Patient no. 18 | De novo | NK | Complex monosomal | 11.4 |
Patient no. 19 | sAML (after MDS) | M1 | 46,XY[20] | 59 |
Patient no. 20 | De novo | NK | 47,XY,+8[21]/46,XY[1] | 1.3 |
Patient no. 21 | De novo | M1 | 46,XY[20] | 8.1 |
Patient no. 22 | De novo | M0 | NK | 1 |
Patient no. 23 | De novo | CMML | 46,XY[20] | 47.1 |
Patient no. 24 | De novo | M1 | 46,XX,DEL(7)(Q22Q36)[20] | 8.6 |
Patient no. 25 | De novo | M4 | Complex monosomal | 10 |
Patient no. 26 | De novo | M5 | 46,XY,ADD(17)(P1?3)[14]/46,XY[8] | 35 |
Patient no. 27 | De novo | NK | 46,XY[20] | 5.5 |
Patient no. 28 | De novo | NK | 46,XX[20] | 0.5 |
Patient no. 29 | De novo | M1 | Complex | 2.4 |
Patient no. 30 | De novo | M1 | 47,XX,+10[37]/46,IDEM,DEL(9)(Q12Q32)[3] | 136.9 |
Patient no. 31 | De novo | M4 | 46,XY[20] | 18.8 |
Patient no. 32 | De novo | M0 | 46,XY[40] | 185 |
Patient no. 33 | De novo | M6 | 46,XY,INV(3)(Q21Q26)[20] | 17.6 |
Patient no. 34 | De novo | M5 | Complex | 80.2 |
Patient no. 35 | De novo | M1 | 47,XX,+21[10]/46,XX[11] | 6.7 |
Patient no. 36 | De novo | M0 | 46,XY,?T(3;7;5)(P24;Q36;Q14)[20] | 66 |
Patient no. 37 | De novo | M0 | 46,XX[30] | 2 |
Patient no. 38 | De novo | M4 | 46,XY,INV(16)(P13Q22)[20] | 29.7 |
Patient no. 39 | sAML (after MDS) | M2 | 46,XY[20] | 5.6 |
Patient no. 40 | De novo | M2 | 46,XX[20] | 3.2 |
Patient no. 41 | De novo | M1 | Complex monosomal | 1 |
Patient no. 42 | De novo | M0 | 45,XX,-7,DER(21)T(7;21)(P11;P11)[20] | 2.8 |
Patient no. 43 | De novo | M1 | 46,XX[20] | 51.6 |
Patient no. 44 | De novo | M4 | Complex monosomal | 23.4 |
Patient no. 45 | De novo | M0 | Complex monosomal | 2.5 |
Patient no. 46 | De novo | M5 | 46,XY,T(9;11)(P21-22;Q23)[20] | 169.9 |
Patient no. 47 | sAML (after MPN) | M0 | 46,XY,DEL(7)(Q22Q36)[21]/46,IDEM,I(21)(Q10)[2] | 5.2 |
Patient no. 48 | De novo | M5 | 46,XY,T(6;9)(P22;Q34)[20] | 41.8 |
Patient no. 49 | De novo | M1 | 46,XX[20] | 21.8 |
Patient no. 50 | De novo | M5 | 46,XX,T(11;17)(Q23;Q12-21)[2]/47,IDEM,?DEL(11)(Q23 OR Q22Q24-)+21[20] | 54.1 |
Patient no. 51 | De novo | M2 | 46,XY[20] | 3.32 |
Patient no. 52 | De novo | M4 | 46,XX[20] | 19.1 |
Patient no. 53 | De novo | M2 | 46,XX[20] | 3.9 |
Patient no. 54 | De novo | M2 | 46,XY[20] | 48.9 |
Patient no. 55 | De novo | M2 | 46,XX[20] | 6.9 |
Patient no. 56 | De novo | NK | Complex monosomal | 17.5 |
Patient no. 57 | De novo | M5 | 47,XY,+21[21]/46,XY[1] | 29 |
Patient no. 58 | De novo | M2 | 45,XY,-7[3]/46,XY[17] | 146 |
Patient no. 59 | De novo | M4 | Complex monosomal | 2.5 |
Patient no. 60 | Patient no. 14 relapse | |||
Patient no. 61 | Patient no. 31 relapse | |||
Patient no. 62 | Patient no. 40 relapse |
FAB, French-American-British classification; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; NK, Not Known; ND, Not Determined; sAML, secondary AML.
Genetic deletion of JAM-C before leukemic onset alters HSPC expansion driven by iMLL-AF9 expression
To test whether JAM-C plays a role in the LSC transcriptional program, we established a mouse model in which conditional knock out of Jam3 can be achieved before leukemic initiation. iMLL-AF9 mice were crossed with Mx1-Cre/Jam3fl/fl mice resulting in iMLL-AF9/Mx1-Cre/Jam3fl/fl mice (called iMLL Jam3fl/fl hereafter). Deletion of Jam3 in hematopoietic cells was induced upon poly (I:C) injection, and AML was initiated by DOX-induced MLL-AF9.37 Leukemia burden was measured by WBC and experiments were stopped when a value of 30 x 103 cells per μL was reached (Figure 2A; supplemental Figure 2A). JAM-C expression was not altered by leukemic transformation and efficient deletion of JAM-C in leukemic long-term (LT) HSCs (L-LT-HSCs), leukemic short-term (ST) HSCs (L-ST-HSC), and leukemic multipotent progenitors-3 (L-MPP-3) was observed upon poly (I:C) treatment (Figure 2B). Jam3 deletion and loss of JAM-C protein expression were already achieved at the time of DOX induction, as shown by quantitative reverse transcription polymerase chain reaction and flow cytometry (Figure 2C; supplemental Figure 2B). Similar WBC increase was observed in iMLL Jam3ko/ko or iMLL Jam3fl/fl leukemic mice as compared with nonleukemic animals (Figure 2D). Increase in red blood cells distribution width values, which preceded that of WBC as described in humans,43 confirmed similar leukemia progression in Jam3–proficient and –deficient leukemic mice (Figure 2E).
Previous reports have shown that MLL-AF9–driven leukemia-initiating cells are found in the L-LT-HSC and leukemic GMP (L-GMP) compartments.32,37,44 Early hematopoietic changes in nonleukemic and leukemic iMLL Jam3fl/fl and iMLL Jam3ko/ko mice was thus analyzed by flow cytometry using the gating strategy described in supplemental Figure 2C.45 As previously reported,37 we found a twofold reduction in the frequency of Lin–Sca+Kit+ cells (LSK) in leukemic mice as compared with healthy animals regardless of JAM-C expression (Figure 2F). Within the LSK compartment, expansion of the L-LT-HSC compartment in diseased mice as compared with healthy controls was JAM-C dependent (Figure 2G). In contrast, expansion of the L-ST-HSC compartment observed in diseased animals was even further increased in Jam3–deficient leukemic mice, reaching >60% of the LSK compartment (Figure 2H). This was at the expense of L-MPP-2, -3 and -4 (supplemental Figure 2D). The twofold expansion of the L-GMP compartment observed in Jam3–proficient leukemic mice as compared with healthy animals was abolished in Jam3–deficient leukemic mice (Figure 2I). Uniform manifold approximation and projection analysis confirmed that expansion of L-LT-HSCs, L-ST-HSCs, and L-GMPs observed in iMLL-AF9 Jam3fl/fl mice was replaced by expansion of a common myeloid progenitor–like compartment in Jam3–deficient leukemic mice (Figure 2J; supplemental Figure 2E).
To avoid interindividual variability of leukemic onset (supplemental Figure 2A), we performed adoptive transfer experiments. Lethally irradiated recipients received transplantation with 106 bone marrow (BM) cells from noninduced naive iMLL-AF9 mice, and Jam3 deletion was induced before or after DOX exposure. The first group received poly (I:C) 1 day after grafting and rested for 2 weeks before DOX induction, group: poly (I:C) -> DOX; whereas the second group was continuously treated with DOX starting on day 1 and received poly (I:C) after 2 weeks, group: DOX -> poly (I:C). We observed a trend toward faster progression of the disease in the group poly (I:C) -> DOX than in the DOX -> poly(I:C), with 3 of 4 mice reaching the end point after 7 weeks of DOX treatment. In contrast, the 3 mice from DOX -> poly (I:C) progressed after 10 weeks (supplemental Figure 3A-B). At end point, the nature of circulating blasts and infiltration of leukemic cells in the liver or spleen were similar between the groups (supplemental Figure 3C-F). In contrast, nonsupervized flow cytometry analysis of Lin–Kit+ (LK) HSPCs highlighted differences in BM content between the groups at end point. Nonleukemic, nonirradiated BM samples were included in the analysis as control. Unsupervised clustering revealed 6 clusters, with the clusters 1 to 5 being underrepresented in the DOX -> poly (I:C) group (Figure 3A). Clusters 1 to 5 contained LSKs whereas cluster 6 corresponded to LK cells lacking Sca-1 expression. L-LT-HSCs and L-ST-HSCs were respectively enriched in cluster 1 and 2, as illustrated by the expression profiles of Sca-1, CD150, CD135, CD48, and CD34 in these 2 clusters (Figure 3B). Clusters 3, 4, and 5 corresponded to MPP-2, MPP-3, and MPP-4, respectively. The proportion of cells in cluster 2, 3, and 4 was greatly increased in the poly (I:C) -> DOX group compared with DOX -> poly (I:C) indicating that deletion of JAM-C before leukemic induction has a profound effect on early steps of hematopoiesis. Finally, LK cells in the poly (I:C) -> DOX group showed a trend toward increased CD117 expression and reduced CD16/32 as compared with the DOX -> poly (I:C) group consistent with increased leukemic common myeloid progenitor–like expansion.
Jam3 deletion rewires the AP-1/TNF-α/NF-κB transcriptional network
To identify molecular mechanisms by which JAM-C regulates L-ST-HSC expansion, we performed bulk mRNA sequencing on L-HSCs (L-HSPC/CD48–) and L-GMPs isolated from the BM of Jam3–proficient and Jam3–deficient diseased mice. All animals were treated with poly (I:C) before leukemia initiation by DOX. A total of 53 genes were upregulated in L-HSCs isolated from Jam3–deficient leukemic mice, whereas only 11 genes, including Jam3, were significantly downregulated (Figure 4A; supplemental Table 3). In L-GMPs isolated from Jam3–deficient leukemic mice, we also observed upregulated genes although the cells did not express JAM-C (Figure 4B).46,47 Gene set enrichment analysis revealed enrichment of pathways related to cell-cell adhesion, TNF-α signaling via NF-κB and AP-1 transcription factor in L-HSCs isolated from leukemic Jam3-deficient mice (Figure 4C). The comparison of DEGs between Jam3–deficient and –proficient leukemic mice highlighted upregulation of several AP-1 family transcription factors including Jun, Fos, Junb, and Jund in leukemic L-HSCs and L-GMPs isolated from Jam3-deficient mice (Figure 4D; supplemental Figure 4). We then questioned whether genes affected by JAM-C deletion allow identification of specific LSC compartments in human AML. Notably, none of the DEGs identified in L-HSC and L-GMP iMLL-AF9 AML were present in the LSC-17 gene list (supplemental Table 4). In contrast, 25 of 56 DEGs found in our study were overexpressed by CD34+ AP-1High leukemic blasts previously identified by single-cell transcriptomic analysis of samples from patients with AML (Figure 4E).28 Our observations suggest that JAM-C expression represses transcription of genes from AP-1 and TNF-α pathways that have been implicated in the transition between the preleukemic and leukemic stage.48-50
The AP-1/TNF-α signature substratifies patients with LSC-17 scores and identifies patients with AML with poor prognosis
To test whether the JAM-C–related differential AP-1/TNF-α signature may reflect a different cell of origin than those proposed by the LSC-17 or the Epithelial-Mesenchymal-Transition (EMT)-related gene expression signature of LT-HSC–derived iMLL-AF9 AML, gene expression correlation was carried out with 3 independent AML cohorts (TCGA, Leucegene, and OHSU). Irrespective of the cohort, 2 major clusters of coregulated genes were identified and named cluster I and cluster II, respectively (Figure 5A; supplemental Figure 5). Cluster I contained JAM3, ZEB1, ITGA6, ERG, and genes from the LSC-17 score including GPR56, DNMT3B, and NYNRIN whereas genes belonging to the AP-1/TNF-α signature were mostly found in cluster II. Gene expression data sets from the 3 cohorts were thus assembled in a single mixed data set representing 871 patient samples to perform unsupervised clustering according to expression of genes from the LSC-17 score and AP-1/TNF-α DEG signature. Four groups of patients expressing inverse, high, or intermediate levels of the 2 gene expression signatures were identified (Figure 5B). This raised the question whether patients stratified by the LSC-17 score may be substratified by the AP-1/TNF-α DEG signature. To address this, the mixed data set was equally split in training and validation cohorts in order to define an ATIC score for LSC-17 substratification. We used the least absolute shrinkage and selection operator (LASSO) algorithm to relate expression of genes from the AP-1/TNF-α signature to patient survival in the training cohort using age and LSC-17 scores as offsets. LASSO was run on 2000 drawings of the training cohort. A weighted sum of gene expression obtained from the LASSO algorithm was fed into a Cox model to define a threshold for the ATIC score using either the maximally selected rank and statistics (Max-Stat) method or the median value of the ATIC score. Quality of the different models was then assessed according to the area under the curve, and accuracy of the 10 best models was tested with respect to median or Max-Stat thresholding. We found that most of the patients were classified as ATICHigh or ATICLow irrespective of the model (supplemental Figure 6; classification occurrence = 10). Only few patients were not repeatedly classified as high or low and had classification occurrence different from 10. Using median thresholding, 2 patients were classified 5 times as high and 5 times as low, resulting in a classification occurrence value of 0 (supplemental Figure 6A), whereas 4 patients belonged to the classification occurrence class 0 using Max-Stat thresholding (supplemental Figure 6B). We therefore chose median thresholding as the most robust method to calculate the ATIC score. Among the selected models, the model with the highest area under the curve and using genes detectable across all platforms (RNA sequencing, nCounter Nanostring, and Affymetrix) allowed us to define the ATIC score as the weighted sum of 14 genes (JAM3, DUSP1, RGS1, H2BC8, NFKBID, ZFP36, SLFN12, GAS5, RPP25L, HEY1, GIMAP4, EFCAB11, CCL4, and MYCN).
Combination of ATIC and LSC-17 scores identified patients with a median survival not reached after 8 years of follow-up in the ATICLow/LSC-17Low arm (Figure 6A; supplemental Figure 6C), whereas patients belonging to the ATICHigh/LSC-17High had a median survival of <1 year. To confirm these results, we tested an independent cohort of 662 adult AML cases for which gene expression was measured using Affymetrix (HOVON cohort). ATIC and LSC-17 scores were significantly associated with disease outcome and respective median survival of 12.3 months for LSC-17High, 132 months for LSC-17Low, 17.1 months for ATICHigh, and 31.1 months for ATICLow (supplemental Figure 6D-E). Despite the excellent predictive value of the LSC-17 score in this cohort, combination of the ATIC score with LSC-17 allowed us to reclassify 139 cases with ATICHigh score in each of the LSC-17 groups (Figure 6B). ATICHigh/LSC-17High and ATICLow/LSC-17Low scores were strongly associated with disease outcome with respective median survival values of 10.6 months and not reached after 200 months. The fact that the ATIC score was obtained from genes regulated upon JAM-C deletion in a mouse MLL-rearranged (MLLr) model called into question whether the ATIC score was specifically associated with known genetic classifiers of AML outcome such as MLLr, TP53 mutation, or other. In the OHSU cohort, patients with MLLr were enriched in the ATICHigh/LSC17Low subgroup and associated with low expression of several stemness genes such as KIAA0125, C19orf77, CPXM1, AKR1C3, CD34, JAM3, or GPR56 (Figure 6C). CEBPA mutations were exclusively found in the LSC17Low group. TP53-mutated AML with myeloid-related changes were enriched in the LSC17High group irrespective of ATIC score. Other AML with myeloid-related changes distributed across all 4 groups, similar to AML with FLT3 and NPM1 mutations.
BMSCs control AP-1 activation whereas JAM-C regulates leukemic cell nesting
Because the ATIC signature has been found after Jam3 deletion in preleukemic cells and substratifies patients with different molecular alterations, our data suggest that the ATIC score reveals stromal cell–dependent disease heterogeneity. To test the functional consequences of JAM-C expression by leukemic cells, we isolated 2 isogenic variants from the parental SKM-1 AML cell line, which expressed JAM-C in a bimodal manner (supplemental Figure 7A). Adhesion of the 2 variant cell lines to the BM stromal cell lines HS-5 or HS-27 was tested upon coculture for 7 hours (supplemental Figure 7B). SKM-1JAM-C+ cells were enriched in the nested fraction irrespective of the stromal cell line, indicating that JAM-C promotes leukemic cell retention under stromal cells (Figure 7A-B). To further explore whether JAM-C controls AP-1 activation, SKM-1 variant cell lines were transduced with AP-1 GFP reporter. Activation of AP-1 reporter cell lines with phorbol myristate acetate induced GFP expression irrespective of JAM-C expression (Figure 7C). Induction of the AP-1 GFP reporter was also observed upon coculture of reporter cells with the HS-5 stromal cell line irrespective of JAM-C expression (Figure 7D; supplemental Figure 7C). In contrast, the AP-1 GFP reporter was not induced upon coculture with the HS-27 cell line (Figure 7E; supplemental Figure 7C), indicating that AP-1 activation depends on the nature of the stromal cells.
Discussion
In this study, we explored the functional significance of JAM-C expression by leukemic subsets in AML. We found that JAM-C expression correlated with GPR56 and was enriched in the group of samples belonging to the LSC-17High arm. This is consistent with previous findings showing that JAM-C and GPR56 identify human AML cells with high engraftment capacity.4,17,51
Enforced GPR56 expression has been shown to accelerate leukemogenesis of HOXA9-transduced hematopoietic cells, whereas silencing GPR56 expression delayed HOXA9/MEIS1-induced AML development.52 However, this was independent of GPR56 binding to collagen III,53 raising the question whether LSC adhesion to BM microenvironment was involved in LSC maintenance. Similarly, the function of JAM-C in leukemogenesis has been addressed through MLL-AF9 retroviral transduction of Jam3–proficient and Jam3–deficient progenitor cells.54 Results showed that survival was slightly reduced in primary recipient mice receiving Jam3–deficient leukemic cells, whereas it was increased in serial transplants suggesting that JAM-C contributes to maintenance of LSC self-renewal. This was attributed to cell intrinsic signaling properties of JAM-C through its direct cis interaction with LRP5 because no defect in homing or adhesion to BMSCs was observed. However, these 2 studies required adoptive transfer and did not address the role of in situ adhesive properties of GPR56 or JAM-C at the time of leukemic transformation.
JAM-C is physiologically downregulated during normal hematopoiesis.47,55,56 Therefore, we thought that JAM-C deletion before leukemic initiation may reveal changes in disease development or gene expression occurring when the first hit takes place in nonprimitive HSC. Jam3 deletion before MLL-AF9 expression in situ results in accumulation of L-ST-HSCs instead of L-LT-HSCs and L-GMPs.37 Such phenotypic alterations are correlated with increased expression of AP-1/TNF-α genes, which has already been reported in CD34+ AML blasts as compared with healthy HSPCs.28,49 This suggests that the ATIC gene signature represents a proxy of the loss of preleukemic cell nesting in specific microanatomical sites and is consistent with the involvement of BMSCs in AP-1 activation in vitro. However, a major limitation of our study is the lack of demonstration that preleukemic cell nesting is altered after JAM-C deletion at the time of leukemic initiation. Future studies using single-cell resolved spatial transcriptomics or proteomics should address this point.
A major finding of our study is the demonstration that the ATIC score allows substratification of patients classified with the LSC-17 score. Although the ATIC score was established based on an MLLr model in which we mimicked loosening of preleukemic cell adhesion to the niche, it allows substratification of patients with different mutational background. This raises the question whether the continuum between myeloproliferative neoplasm, myelodysplastic syndrome, and AML diseases relies on differential niche anchoring of preleukemic cells in specific microanatomical sites that can be detected by LSC-17 and ATIC scores.
Acknowledgments
The authors thank Manon Richaud and Françoise Mallet for invaluable help in flow cytometry analysis and cell sorting, Jean-Baptiste Marty for taking care of animal breeding and the CiBi core-facility for bioinformatic support. The authors thank P. Valk and M. Sanders for providing survival status for the HOVON/SAKK cohort.
This work has been supported by Ligue Nationale Contre le Cancer (Equipe labellisée 2020), Cancérôpole PACA, and Inca PRT-K16 (M.A.-L.) and GIRCI (M.A.-L. and M.-A.H.). J.M.P.G., and C.T. were supported by grants from the Société Française d’Hématologie. Generation of the iMLL-AF9 mouse model was supported by the Swiss National Science Foundation (SNF-31000A_173224, 2017-2020 [J.S.]).
Authorship
Contribution: J.M.P.G. performed experiments and wrote the manuscript; C.T., F.B., and M.D.G. performed experiments, and M.D. helped with mouse experiments; M.B., J.V., S.G., C.Z., J.-F.S., and J.-M.B. were in charge of bioinformatic analysis and data set processing; T.C. provided Jam3-floxed mice, and J.S. provided the iMLL-AF9 model; J.H. and G.S. provided clinical data from the Leucegene cohort; N.V. and M.-A.H. provided patient samples and clinical data from the NCT02320656 clinical trial; V.G.-B. interpreted clinical data, histological results, and blood smears; S.J.C.M. helped with interpretation of results; C.F. and M.A.L. were responsible for project supervision and coordination, experimental design, and manuscript preparation; all authors read and approved the manuscript.
Conflict-of-interest disclosure: The authors declare no competing financial interests.
Correspondence: Michel Aurrand-Lions, Department of Onco-Haematology and Immuno-Oncology, Cancerology Research Center of Marseille, CRCM, INSERM UMR1068, CNRS UMR7258, Aix-Marseille Université U105, Institut Paoli-Calmettes, 27 Blvd Leï Roure, CS30059, Cedex 09, 13273 Marseille, France; email: [email protected].
References
Author notes
Data sets have been deposited in the Gene Expression Omnibus database (accession number GSE235693).
All bioinformatic pipelines are available upon request from the corresponding author, Michel Aurrand-Lions ([email protected]).
The full-text version of this article contains a data supplement.